For therapeutic correction, currently used doses (range 0.5–2 × 1013 vg/kg) using AAV serotypes 5 or 8 are sufficient to stop or reduce factor IX administrations to stop bleeding episodes in patients suffering from hemophilia B or to stop daily phototherapy in patients suffering from Crigler–Najjar syndrome. Here, F9 is linked to hemophilia B.